
Bolt Biotherapeutics Investor Relations Material
Latest events

Status Update
Bolt Biotherapeutics
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Bolt Biotherapeutics Inc
Access all reports
Bolt Biotherapeutics Inc. is a clinical-stage biotechnology company engaged in developing innovative immunotherapies for cancer treatment. The company's proprietary technology, Boltbody Immune-stimulating Antibody Conjugate, represents a novel approach in immuno-oncology, aiming to transform "cold" tumors into "hot" tumors by engaging and activating myeloid cells to directly attack tumor cells. Bolt Biotherapeutics is advancing its lead clinical candidate, BDC-1001, a HER2-targeting Boltbody ISAC for the treatment of patients with HER2-positive solid tumors. Additionally, the company is developing BDC-3042, a myeloid modulating agonistic antibody aimed at reprogramming tumor-associated macrophages to enhance anti-tumor immunity, with plans to enter clinical trials. The company is headquartered in Redwood City, California, and its shares are listed on the Nasdaq.
Latest articles
)
Eli Lilly: The Pharma Giant Behind Mounjaro and Zepbound
Eli Lilly's journey from insulin pioneer to global pharma giant, leading innovation in diabetes, obesity, and the future of metabolic health.
30 Jun 2025
)
500 Years of Craft, One Family Legacy: Beretta Holding's Global Expansion
How Beretta Holding managed to transform from a 16th-century gun barrel producer into a global industrial group while preserving 500 years of legacy.
27 Jun 2025
)
Shuntaro Furukawa: The Sixth President of Nintendo
Shuntaro Furukawa, Nintendo's sixth president, went from a childhood fan to leading the company through global expansion and the launch of Switch 2.
23 Jun 2025
Ticker symbol
BOLT
Country
🇺🇸 United States